 |
|
Trends in the Risks and Benefits to Patients With Cancer Participating in Phase 1 Clinical Trials
Thomas G. Roberts, Jr, MD, MSocSci;
Bernardo H. Goulart, MD;
Lee Squitieri;
Sarah C. Stallings, PhD;
Elkan F. Halpern, PhD;
Bruce A. Chabner, MD;
G. Scott Gazelle, MD, MPH, PhD;
Stan N. Finkelstein, MD;
Jeffrey W. Clark, MD
JAMA. 2004;292:2130-2140.
Context In the past, cancer patients entering phase 1 studies confronted the prospects of high risk and unlikely benefit. Over the last decade, cancer drugs under development have become more targeted, and the clinical research environment has become more scrutinized. The impact of these changes on the risks and benefits to patients who participate in phase 1 cancer trials is unknown.
Objective To determine trends in the rates of treatment-related (toxic) death, objective response, and serious toxicity and to identify factors associated with these outcomes.
Data Sources We searched abstracts and journal articles reporting the results of phase 1 cancer treatment trials originally submitted to annual meetings of the American Society of Clinical Oncology (ASCO) from 1991 through 2002.
Study Selection We focused on published single-agent trials that enrolled patients with advanced solid tumors and excluded studies testing agents already approved by the US Food and Drug Administration at the time of the ASCO presentation.
Data Extraction Multiple observers independently extracted information on trial design, location, sponsorship, types of tumors treated, drug class, route of administration, and clinical outcomes.
Data Synthesis The overall toxic death rate for 213 studies (involving 6474 cancer patients) published in peer-reviewed journals was 0.54%, while the overall objective response rate was 3.8%. Toxic death rates decreased over the study period, from 1.1% over the first 4 years of the study (1991-1994) to 0.06% over the most recent 4-year period (1999-2002) (P<.01). Response rates also decreased but by proportionally much less. After adjusting for characteristics of the experimental trials and the investigational agents, the odds of a patient dying from an experimental treatment while participating in a trial submitted during the most recent 4-year period were less than one tenth those of a patient participating in a trial submitted during the first 4-year period (odds ratio, 0.09; 95% confidence interval, 0.01-0.67; P = .009). In comparison, the adjusted odds of a patient experiencing an objective response over the same time periods decreased by approximately half (odds ratio, 0.46; 95% confidence interval, 0.32-0.66; P<.001).
Conclusions The level of risk experienced by cancer patients who participate in phase 1 treatment trials appears to have improved over the 12-year period from 1991 through 2002. Because toxic death rates have decreased more quickly than have objective response rates, the ratio of risk to benefit may have also improved. These changes relate in part to the targeted and less-toxic nature of newer cancer drugs and are coincident with the increased attention that has been paid to the safety of clinical research over the time period we analyzed.
Author Affiliations: Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass (Drs Roberts, Goulart, Chabner, and Clark); Program on the Pharmaceutical Industry, Massachusetts Institute of Technology, Cambridge (Drs Roberts, Stallings, and Finkelstein and Ms Squitieri); Institute for Technology Assessment, Massachusetts General Hospital (Drs Roberts, Halpern, and Gazelle); Dana-Farber/Harvard Cancer Center, Harvard Medical School (Drs Roberts, Chabner, and Clark).
RELATED LETTERS
Trends in the Risks and Benefits to Patients With Cancer in Phase 1 Clinical Trials
Susan Ross
JAMA. 2005;293(7):795.
EXTRACT
| FULL TEXT
Trends in the Risks and Benefits to Patients With Cancer in Phase 1 Clinical Trials—Reply
Thomas G. Roberts, Jr, Bernardo H. Goulart, Jeffrey W. Clark, and Bruce A. Chabner
JAMA. 2005;293(7):795.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Risks and Benefits of Phase 1 Clinical Trials Evaluating New Anticancer Agents: A Case for More Innovation
Eric X. Chen and Ian F. Tannock
JAMA. 2004;292(17):2150-2151.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The Multi-Institutional Phase I Study: Disadvantages Without Advantages?
Verweij et al.
JCO 2008;26:1915-1916.
FULL TEXT
Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy
Italiano et al.
Ann Oncol 2008;19:787-792.
ABSTRACT
| FULL TEXT
Analysis of Phase II Studies on Targeted Agents and Subsequent Phase III Trials: What Are the Predictors for Success?
Chan et al.
JCO 2008;26:1511-1518.
ABSTRACT
| FULL TEXT
Participants in Phase 1 Oncology Research Trials: Are They Vulnerable?
Seidenfeld et al.
Arch Intern Med 2008;168:16-20.
ABSTRACT
| FULL TEXT
Trends in the Use and Role of Biomarkers in Phase I Oncology Trials
Goulart et al.
Clin. Cancer Res. 2007;13:6719-6726.
ABSTRACT
| FULL TEXT
Translation of Innovative Designs Into Phase I Trials
Rogatko et al.
JCO 2007;25:4982-4986.
ABSTRACT
| FULL TEXT
Complementary and Alternative Medicine Among Advanced Cancer Patients Enrolled on Phase I Trials: A Study of Prognosis, Quality of Life, and Preferences for Decision Making
Hlubocky et al.
JCO 2007;25:548-554.
ABSTRACT
| FULL TEXT
Dynamic and Modern: Bringing the Ethics of Phase I Trials Up to Date
Camidge et al.
JCO 2006;24:5178-5179.
FULL TEXT
Phase I Trials May Not Need to Be Viewed As Extraordinarily Different From Other Clinical Research
Sharma
JCO 2006;24:e47-e47.
FULL TEXT
Phase 1 clinical trials: not just for safety anymore?
Khandekar and Khandekar
Arch Intern Med 2006;166:1440-1441.
FULL TEXT
"Therapeutic intent" in phase 1 oncology trials: a justifiable objective.
Markman
Arch Intern Med 2006;166:1446-1448.
FULL TEXT
Rethinking Risk-Benefit Assessment for Phase I Cancer Trials
Joffe and Miller
JCO 2006;24:2987-2990.
FULL TEXT
Pediatric Phase I Trials in Oncology: An Analysis of Study Conduct Efficiency
Lee et al.
JCO 2005;23:8431-8441.
ABSTRACT
| FULL TEXT
Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002
Horstmann et al.
NEJM 2005;352:895-904.
ABSTRACT
| FULL TEXT
Risks and Benefits of Phase 1 Oncology Trials, Revisited
Kurzrock and Benjamin
NEJM 2005;352:930-932.
FULL TEXT
Trends in the Risks and Benefits to Patients With Cancer in Phase 1 Clinical Trials
Ross
JAMA 2005;293:795-795.
FULL TEXT
Risks and Benefits of Phase 1 Clinical Trials Evaluating New Anticancer Agents: A Case for More Innovation
Chen and Tannock
JAMA 2004;292:2150-2151.
FULL TEXT
|
